<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39230829</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2193-8229</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Infectious diseases and therapy</Title><ISOAbbreviation>Infect Dis Ther</ISOAbbreviation></Journal><ArticleTitle>Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19.</ArticleTitle><Pagination><StartPage>2123</StartPage><EndPage>2134</EndPage><MedlinePgn>2123-2134</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40121-024-01031-z</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The monoclonal antibody therapies bamlanivimab (BAM) + etesevimab (ETE) received emergency use authorization (EUA) from the US Food and Drug Administration (February 9, 2021) for treatment of mild-to-moderate COVID-19. The EUA of BAM + ETE was revoked (December 14, 2023) due to the high prevalence of BAM + ETE-resistant variants of SARS-CoV-2. Efficacy and safety of 700/1400 mg and 2800/2800 mg BAM + ETE are well established and published; however, efficacy and safety of 350/700 mg BAM + ETE have not been disclosed to date.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This portion of phase 3, BLAZE-1 trial (J2X-MC-PYAB) enrolled patients (between June 17, 2020 and April 9, 2021) with mild-to-moderate COVID-19 within 3 days of laboratory diagnosis of SARS-CoV-2 infection. In total, 354 patients with at least one risk factor for severe COVID-19 were enrolled, randomized (2:3), and infused with placebo (N = 141) or 350/700 mg BAM + ETE (N = 213), over ~ 8 min. Primary endpoint was to assess proportion of patients with persistently high SARS-CoV-2 viral load (PHVL) (log viral load &gt; 5.27) 7 days after infusion.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients were aged (mean) 53 years, 49.7% female, and 82.7% White. Seven days after drug infusion, 10.8% (95% confidence interval: 6.6, 15.0; p &lt; 0.001) of BAM + ETE-treated patients and 34.8% (26.9, 42.6) of placebo-treated patients had PHVL, and the viral load change from baseline (least square mean [standard error]) was - 3.50 (0.15; p &lt; 0.001) in BAM + ETE-treated patients versus - 2.51 (0.19) in placebo-treated patients. The majority of treatment-emergent adverse events were considered mild or moderate in severity (BAM + ETE: 6.6%; placebo: 14.2%). No deaths were reported.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Consistent with previous studies, patients treated with BAM + ETE (350/700 mg) had a significantly lower proportion of PHVL and greater reduction in viral load compared with placebo. The overall safety profile is consistent with higher doses of BAM + ETE. Infusions of over ~ 8 min did not result in meaningful increase in incidence of TEAEs compared to higher doses of BAM + ETE administered over 30-60 min.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Clinical trial.gov identifier, NCT04427501.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Dipak R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, 893 S Delaware St, Indianapolis, IN, 46220, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macpherson</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, 893 S Delaware St, Indianapolis, IN, 46220, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohm</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, 893 S Delaware St, Indianapolis, IN, 46220, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Upadhyaya</LastName><ForeName>Himanshu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, 893 S Delaware St, Indianapolis, IN, 46220, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deveau</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, 893 S Delaware St, Indianapolis, IN, 46220, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nirula</LastName><ForeName>Ajay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, 893 S Delaware St, Indianapolis, IN, 46220, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klekotka</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, 893 S Delaware St, Indianapolis, IN, 46220, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, 893 S Delaware St, Indianapolis, IN, 46220, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hufford</LastName><ForeName>Matthew M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, 893 S Delaware St, Indianapolis, IN, 46220, USA. hufford_matthew@lilly.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04427501</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Infect Dis Ther</MedlineTA><NlmUniqueID>101634499</NlmUniqueID><ISSNLinking>2193-6382</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BLAZE-1</Keyword><Keyword MajorTopicYN="N">Bamlanivimab</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Clinical trial</Keyword><Keyword MajorTopicYN="N">Etesevimab</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList><CoiStatement>Dipak R. Patel, Lisa Macpherson, Martin Bohm, Carmen Deveau, Paul Klekotka, Mark Williams, and Matthew M. Hufford are employees and/or stockholders of Eli Lilly and Company. Himanshu Upadhyaya was an employee at Eli Lilly and Company at the time of study and development of the manuscript and is currently employed by Supernus Pharmaceuticals, Inc. Rockville, Maryland, USA. Ajay Nirula was an employee at Eli Lilly and Company at the time of study and development of the manuscript and is currently employed by Recludix Pharma, San Diego, California, USA.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>4</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>4</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>4</Day><Hour>11</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39230829</ArticleId><ArticleId IdType="pmc">PMC11416433</ArticleId><ArticleId IdType="doi">10.1007/s40121-024-01031-z</ArticleId><ArticleId IdType="pii">10.1007/s40121-024-01031-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>COVID-19 Treatment Guidelines. National Institute of Health. Available: https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/. Accessed 31 Mar 2022.</Citation></Reference><Reference><Citation>Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164635</ArticleId><ArticleId IdType="pubmed">32132184</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Zhang Y, Wu L, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020;181(894–904):e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7144619</ArticleId><ArticleId IdType="pubmed">32275855</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095016</ArticleId><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton DJ, Wrobel AG, Xu P, et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature. 2020;588:327–30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116727</ArticleId><ArticleId IdType="pubmed">32942285</ArticleId></ArticleIdList></Reference><Reference><Citation>Bamlanivimab/Etesevimab. 2023. Available https://aspr.hhs.gov/COVID-19/Therapeutics/Products/Bamlanivimab-etesevimab/Pages/default.aspx. Accessed 22 Apr 2024.</Citation></Reference><Reference><Citation>Fact sheet for health care providers Emergency Use Authorization (EUA) of bamlanivimab and etesevimab. Food and Drug Administration, 2021. Available: https://www.fda.gov/media/145802/download. Accessed 22 Feb 2022.</Citation></Reference><Reference><Citation>Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021;385:1382–92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314785</ArticleId><ArticleId IdType="pubmed">34260849</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougan M, Azizad M, Mocherla B, et al. A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. Clin Infect Dis. 2021;75:e440–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9402688</ArticleId><ArticleId IdType="pubmed">34718468</ArticleId></ArticleIdList></Reference><Reference><Citation>Behr CL, Joynt Maddox KE, Meara E, Epstein AM, Orav EJ, Barnett ML. Anti-SARS-CoV-2 monoclonal antibody distribution to high-risk Medicare beneficiaries, 2020–2021. JAMA. 2022;327:980–3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8904305</ArticleId><ArticleId IdType="pubmed">35119452</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols RM, Macpherson L, Patel DR, Yeh WW, Peppercorn A. Effect of bamlanivimab as monotherapy or in combination with etesevimab or sotrovimab on persistently high viral load in patients with mild-to-moderate COVID-19: a randomized, phase 2 BLAZE-4 trial. Infect Dis Ther. 2024;13(2):401–11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10904692</ArticleId><ArticleId IdType="pubmed">38291279</ArticleId></ArticleIdList></Reference><Reference><Citation>IV PUSH VS IV INFUSION: WHICH ONE’S BETTER? 2017. Available: https://www.vitamininjections.co.uk/iv-push-vs-iv-infusion-which-is-better/. Accessed 7 Feb 2024.</Citation></Reference><Reference><Citation>Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632–44. 10.1001/jama.2021.0202</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7821080</ArticleId><ArticleId IdType="pubmed">33475701</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidance for industry. Covid-19: developing drugs and biological products for treatment or prevention. Food and Drug Administration, 2020. Available: https://www.fda.gov/media/137926/download. Accessed 3 Oct 2021.</Citation></Reference><Reference><Citation>Firth D. Bias reduction of maximum likelihood estimates Get access Arrow. Biometrika. 1993;80:27–38.</Citation></Reference><Reference><Citation>Sheward DJ, Kim C, Ehling RA, et al. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study. Lancet Infect Dis. 2022;22(6):813–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8930016</ArticleId><ArticleId IdType="pubmed">35305699</ArticleId></ArticleIdList></Reference><Reference><Citation>VanBlargan LA, Errico JM, Halfmann PJ, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med. 2022;28(3):490–5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8767531</ArticleId><ArticleId IdType="pubmed">35046573</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>